EP0180453A2 - Kontrollvorrichtung für eine Pumpe für die Photoaktivierung in einem Patientenbehandlungssystem - Google Patents

Kontrollvorrichtung für eine Pumpe für die Photoaktivierung in einem Patientenbehandlungssystem Download PDF

Info

Publication number
EP0180453A2
EP0180453A2 EP85307808A EP85307808A EP0180453A2 EP 0180453 A2 EP0180453 A2 EP 0180453A2 EP 85307808 A EP85307808 A EP 85307808A EP 85307808 A EP85307808 A EP 85307808A EP 0180453 A2 EP0180453 A2 EP 0180453A2
Authority
EP
European Patent Office
Prior art keywords
blood
sensors
tab
patient
stepper motor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP85307808A
Other languages
English (en)
French (fr)
Other versions
EP0180453A3 (de
Inventor
Thomas Paul Hartranft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
McNeilab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeilab Inc filed Critical McNeilab Inc
Publication of EP0180453A2 publication Critical patent/EP0180453A2/de
Publication of EP0180453A3 publication Critical patent/EP0180453A3/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02H—EMERGENCY PROTECTIVE CIRCUIT ARRANGEMENTS
    • H02H7/00—Emergency protective circuit arrangements specially adapted for specific types of electric machines or apparatus or for sectionalised protection of cable or line systems, and effecting automatic switching in the event of an undesired change from normal working conditions
    • H02H7/08—Emergency protective circuit arrangements specially adapted for specific types of electric machines or apparatus or for sectionalised protection of cable or line systems, and effecting automatic switching in the event of an undesired change from normal working conditions for dynamo-electric motors
    • H02H7/093—Emergency protective circuit arrangements specially adapted for specific types of electric machines or apparatus or for sectionalised protection of cable or line systems, and effecting automatic switching in the event of an undesired change from normal working conditions for dynamo-electric motors against increase beyond, or decrease below, a predetermined level of rotational speed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3622—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit
    • A61M1/36222—Details related to the interface between cassette and machine
    • A61M1/362223—Details related to the interface between cassette and machine the interface being evacuated interfaces to enhance contact
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3622—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit
    • A61M1/36224—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit with sensing means or components thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3622—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit
    • A61M1/36225—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit with blood pumping means or components thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3622—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit
    • A61M1/36226—Constructional details of cassettes, e.g. specific details on material or shape
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3643—Priming, rinsing before or after use
    • A61M1/3644—Mode of operation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A61M1/3696—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3622—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit
    • A61M1/36222—Details related to the interface between cassette and machine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3622—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit
    • A61M1/36226—Constructional details of cassettes, e.g. specific details on material or shape
    • A61M1/362266—Means for adding solutions or substances to the blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3643—Priming, rinsing before or after use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01H—ELECTRIC SWITCHES; RELAYS; SELECTORS; EMERGENCY PROTECTIVE DEVICES
    • H01H71/00—Details of the protective switches or relays covered by groups H01H73/00 - H01H83/00
    • H01H2071/006—Provisions for user interfaces for electrical protection devices

Definitions

  • This invention relates to the field of treating cells with photoactivatable compounds and radiation which activates the compound thereby affecting the cells and specifically, relates to clinically useful systems for the extracorporeal treatment of blood cells, especially leukocytes, with UV radiation, and most particularly to a stepper motor anticoagulation reagent infusion pump monitor.
  • lymphocytes a number of human disease states may be characterized by the overproduction of certain types of leukocytes, including lymphocytes, in comparison to other populations of cells which normally comprise whole blood. Excessive or abnormal lymphocyte populations result in numerous adverse effects to patients including the functional impairment of bodily organs, leukocyte mediated autoimmune diseases and leukemia related disorders many of which often ultimately result in fatality.
  • U.S. Patent Nos. 4,321,919; 4,398,906; 4,428,744; and 4,464,166 to Edelson describe methods for treating blood whereby the operation or viability of certain cellular populations may be moderated thereby providing relief for these patients.
  • the methods comprise treating the blood with a dissolved photoactivatable drug, such as psoralen, which is capable of forming photoadducts with DNA in the presence of U.V. radiation. It is believed that covalent bonding results between the psoralen and the lymphocyte nucleic acid thereby effecting metabolic inhibition of the thusly treated cells.
  • the cells are returned to the patient where they are thought to be cleared by natural processes but at an accelerated'pace believed attributable to disruption of membrane integrity, alteration of DNA within the cell, or the like conditions often associated with substantial loss of cellular effectiveness or viability.
  • Edelson's methods have been experimentally shown to provide great relief to patients suffering from leukocyte mediated diseases, numerous practical problems remained and required solutions.
  • Edelson fails to provide a suitable apparatus for applying radiation to the cells, e.g. via a treatment station, in an economical and efficacious manner, or a system for incorporating a treatment station providing for the treatment of a patient in a clinically acceptable format.
  • the disposable cassette described therein comprises a plurality of fluorescent tube-like light sources such as the U.V.A. emitting Sylvania F8TS/BLB bulb, which are individually, coaxially mounted in tubes of larger diameter which are, in turn, coaxially mounted in sealing arrangement within second outer tubes of even larger diameter thereby forming a structure having two generally elongated, cylindrical cavities about each radiation source.
  • the inner cavity preferably communicates with the atmosphere thereby facilitating cooling of the radiation source.
  • the second tube forming the outer cavity further comprises inlet and outlet means for receiving and discharging, respectively, the cells to be irradiated.
  • a plurality of these structures are "ganged" and suitable connections made between inlets and outlets of adjacent members to provide for serpentine flow of cells through each outer cavity.
  • continuous flow of the cells through the plurality of cavities surrounding the centrally disposed radiation sources facilitates thorough treatment of the cells. Additional, detailed description of the Taylor device may be obtained by direct reference to the p-ublished-European application, the relevant aspects of which are fully incorporated herein by reference .
  • the Taylor device require a clinically acceptable instrument to house the device and to provide the cells to be treated in an appropriate form. It is an object of the present invention to provide such device.
  • the Edelson methods have been performed utilizing a generally impractical and unwieldy apparatus consisting o a large, desk-size metal box containing a series of flexible, relatively transparent plastic bags through which patient blood was pumped. As the blood flowed through each bag, it was irradiated on either side by a plurality of ultraviolet emitting, standard sized, "fluorescent" type tubes housed within the box. Blood flow was generated by means of a separate pump located nearby and connected to the plastic bags as well as source and drain reservoirs by flexible tubing.
  • a stepper motor pump monitor for use with methods for extracorporeally photoactivating a photoactivatable reagent in contact with blood cells comprising the steps of collecting and separating on a continuous basis blood from a patient while the patient is connected to the apparatus, returning undesired blood portions obtained during separation, disconnecting tne patient from the treatment system while the desired portion is photoactivatably treated whereupon the thusly treated cells are returned to the patient.
  • the various aspects of such photoactivation treatment are accomplished safely by breaking the entire procedure down into three stages or modes.
  • the apparatus in the first mode or phase, collects and separates blood on a continuous basis as it is withdrawn from the patient and to return unwanted portions to the patient while the patient remains connected to the apparatus. Thereafter, prior to energizing the irradiation sources for photoactivating the photoactivatable reagent in contact with the desired blood portion, the patient is disconnected from the machine thereby physically and electrically isolating him (or her) from the energizing high voltages, a potential source of harm. Following photoactivation, the treated cells may then be facilely returned to the patient utilizing a variety of techniques, the preferred being a simple drip chamber gravity feed infusion line.
  • Figures 1, 2 and 3 show various aspects of the apparatus developed by the assignee hereof for extracorporeally treating a patient based in part upon the scientific discoveries of Edelson.
  • the design, construction and operation of the apparatus 10 is the result of a number of separate inventions some of which form the subject matter of copending European patent applications No. (ref: ECP 102, Inventor: Goss) entitled “Three Phase Irradiation Treatment Process” and No. (ref: ECP 103, Inventor: King) entitled “Automated Photophoresis Blood Portion Control Methods and Apparatus", both filed concurrently with this application, and of the following United States patent applications, which are assigned to the present Applicants and were all filed on 29th October 1984.
  • USSN 665 833 Inventor: King - "Electronic Control Methods for Puraphoresis Apparatus”; USSN 665 831 Inventor: Troutner - "Valve Apparatus for Photoactivation Patient Treatment System”; USSN 665 327 Inventor: King et al - "Patient Photophoresis Treatment Apparatus and Method”; USSN 665 817 Inventor: Troutner - "Cassette Drawer Assembly for Photoactivation Treatment System”.
  • the operation of the device and performance of the methods can be divided into three basic phases or modes, depicted in part by Figures I and 2.
  • the first phase is shown substantially in Figure 1 wherein the patient is connected at the point shown such as by veni-puncture or the like methods well-known and developed to a high degree in the dialysis arts.
  • Patient blood as it flows to the apparatus 10 (alternately referred to herein as the puvaphoresis apparatus or system) is preferably infused, under control of pump 11, with an anti-coagulation agent contained in container 20 hung from stand 15.
  • clamping means 16a which has the dual function of also controlling flow in the reverse direction as well as flow to return container 21; clamp 16a acting as an "or" valve.
  • This continuous centrifuge available commercially from suppliers such as Dideco and others, is preferably capable of continuously separating blood based on the differing densities of the individual blood components.
  • Continuous centrifuge as used herein means that, as blood flows into the centrifuge through line 24, it accumulates within the rotating centrifuge bowl and is separated so that low density components are emitted after a certain minimum volume has been reached within the centrifuge bowl and as additional blood is added.
  • the continuous centrifuge in effect acts as a hybrid between a pure online system and a pure batch system. This occurs because the centrifuge bowl has a capacity to capacity to hold most, if not all, of the most dense portion, typically erythrocytes or red blood cells while emitting lower density portions such as plasma and leukocytes (white blood cells) as whole blood is continuously added. At some point, however, the reservoir volume of the centrifuge is filled with the higher density components and further separation cannot be effectively obtained.
  • the operator Prior to that point, the operator, by viewing the uppermost portion of the centrifuge bowl through magnifying observation point port 14 of the centrifuge cover, can detect qualitatively when the centrifuge emits plasma (as opposed to priming solution), leukocyte enriched portions and nonleukocyte enriched portions such as erythrocytes. Based on the operator's observations, he or she enters through control panel 19 (specifically via panel portion 42) the identification of the individual blood portions as they are emitted from the centrifuge. Based on this information, entered by keys 44 (e.g.
  • apparatus 10 controls valve mechanism 16c to direct the leukocyte enriched portion and a predetermined volume of plasma into plasma-leukocyte enriched container 22 while excess plasma, air, priming fluids, erythrocytes etc. are directed to container 23.
  • the operator directs that the bowl be emptied (see Figure 3) by suitable data key entry whereupon the contents of container 23 and centrifuge 13 are advantageously pumped into return container 21 by means of pump 12 under the control of valves 16a and c.
  • the foregoing steps may be repeated a number of times or cycles before the desired volume of leukocyte enriched blood and plasma is obtained for further treatment, in each instance the undesired portions being first collected in container 23 and then pumped to return container 21.
  • the erythrocyte enriched portion which is pumped into return bag 21 is gravity fed back to the patient through a drip infusion operation and controlled by valve 16b. It is preferred that gravity feed be employed rather than pumping the blood back to the patient via pump 12 in order to avoid potential pressurization problems at the infusion insertion site at the patient, and also to avoid foaming or other air related dangers.
  • line 24 may be expected to contain sterilized air which is preferably removed by suitable priming operations utilizing the anti-coagulation agent in container 20; both the air and the priming solution being collected in container 23.
  • the predetermination of the leukocyte enriched volume and plasma volume to be collected within container 22 is selected largely in accordance with the individual volume capacities of the containers as well as the treatment cassette to be described later. Accordingly, these volumes are chosen in order to preferably optimize handling efficiency and to ensure patient safety. For instance, one preferred selection would include the settings: 250 ml total buffy coat or leukocyte enriched portion and 300 ml of plasma to be collected within container 22.
  • a second tubing set for the second operating mode of apparatus 10 is shown with leukocyte enriched container 22 connected via tubing line 24' through valve 16c, blood pump 12 to the treatment cassette assembly 17 with a return line 36 to reservoir container 35.
  • the tubing set for the second mode will also preferably include container 34 for providing a priming solution for evacuating air contained within tubing set 24' and the cassette treatment module, described in copending application of Taylor, U.S.S.N. 650,602.
  • Taylor cassette comprises a plurality of ganged cylindrical cavities each of which is concentrically mounted around a cylindrical irradiation source in turn powered by apparatus 10.
  • the exposure time on the right hand portion of the panel 43 is set in accordance with physician determined criteria via knob 41.
  • the central control means of the apparatus 10 calculates and displays (50) via central processing unit and memory stored software, the exposure time remaining at the onset of irradiation treatment and as the treatment progresses.
  • Section 43 of the control panel also includes three operator controlled entry data keys 44 whereby the first step, PRIME, may be initiated whereupon the priming solution from container 34 is pumped via blood pump 12 through tubing set 24' and the treatment cassette emptying into reservoir 35.
  • the treatment cassette container assembly 17 further comprises air bubble detectors on the tubing to and from the cassette for generating a signal responsive to the presence of air, said signals being conveyed to the central control means for signaling the presence of air about to enter the treatment cassette.
  • the presence of the air indicates the evacuation of container 22 and signals the end of the first treatment pass.
  • the central control means reverses the direction of blood pump 12 which draws blood from container 35 back through the treatment cassette through the blood pump and to container 22.
  • the actual direction of the blood flow through the treatment cassette is of no significance as flow in either direction is equally photoactivated.
  • An advantage gained by reversing direction is the hydrodynamic mixing of blood as it is passed through the container.
  • Container 22 is then ideally removed to stand 15 and a third tubing set connected to container 22 for reinfusion of the treated blood portion into the patient.
  • the patient is preferably disconnected from the machine thereby adding to his (or her) comfort level by permitting him freedom to move about but also concommitantly, increasing his safety level as he (or she) is not connected to the machine when the high voltages, necessary to drive the irradiation sources, are present.
  • container 22 would have three connection ports; one for the first mode collection of the leukocyte enriched blood portion, one for the second mode treatment phase shown by Figure 2, and the third set for the third mode wherein treated blood is reinfused to the patient.
  • the control panel 19 of the apparatus 10 is shown with the key board entry buttons 44 each ideally having a light 45 which, when lit, preferably indicates the stage of the operation.
  • the key board entry buttons 44 are preferably placed in sequential order thereby assisting the operator in learning the system and performing the steps in the correct order.
  • the central control means will preferably be programmed to prevent out of step sequences from being attempted.
  • Display 46 indicates the volume of leukocyte enriched blood collected in container 22.
  • a manual override switch contained within apparatus 10 such as behind access doors 18 (see Figures 1 and 2) for allowing an experienced operator to select any step out of sequence in the unlikely circumstance that such may be necessary to return all blood to the patient in the event of a machine failure.
  • the central portion of panel 19 contains power switch 51 as well as blood pump speed control 40 whereby the operator may select the speed with which the blood is withdrawn from the patient and pumped through the system during either collection or treatment phases. Also included in the central section are liohts 47, Alphanumeric display 49 incicates alarms and status regarding the machine's sequential operations. Status lights 47 are preferably provided in green, yellow, and red colors in order to provide at a glance the overall operating status of apparatus 10. Further included is a mute reset button 48 for quieting an audible alarm activated in the event an alarm condition occurs and operator input is required.
  • upper access door 18 will preferably include mechanical means for assisting in the securement of containers 22, 23, 34, and 35. It may also optionally be outfitted with a transparent or translucent opening in the area beneath container 22 for providing at a glance information regarding the illumination status of the irradiation treatment cassette during the treatment phase. For instance, if the window is of sufficient size, the operator may readily determine that each irradiation source within the treatment cassette is illuminated as desired. Naturally, the material comprising such window is preferably selected in order to contain harmful radiation, if any, within apparatus 10.
  • the aforedescribed photophoresis blood treatment apparatus is made largely possible by automated control methods for directing the blood portions derived from the continuous centrifuge into particular containers.
  • the automated methods perform in accordance with preset volume determinations which are manually entered pursuant to a physician's direction.
  • These predetermined volumes specify the volume to be contained within the buffy coat or leukocyte enriched container 22 by setting forth the volume of plasma and the volume of leukocyte enriched blood portion to be contained therein. Additionally included within these condition setting parameters is preferably the ability to set forth the number of cycles of blood collection and separation required or desired in order to obtain the desired blood volumes.
  • the volumes collected are determined in accordance with the blood volume pumped by the blood pump. This may be suitably monitored and communicated to the central control means by specifically monitoring the speed of the blood pump rotation. Rotation may be conveniently monitored such as by attachment of a slotted disk to the shaft and the passage of slots determined by an optical or other electrical or mechanical sensor means. The resultant periodic signal may be conveniently correlated with speed of rotation by circuit designs well-known in the art. The rotational speed.coupled "with the known volume pumping characteristics of the pump, will provide the necessary information to permit calculation of the volume of blood pumped.
  • the ideal procedure would be as follows.
  • the operator primes the tubing set, the blood pump, and the centrifuge with the anti-coagulant solution contained in container 20.
  • blood is withdrawn from the patient and pumped by the blood pump into the rotating centrifuge.
  • This priming solution is automatically directed into container 23.
  • the priming solution will be completely displaced from the rotating centrifuge and plasma will begin to emerge. This emergence may be directly observed through port 14 whereupon the operator presses the PLASMA key on control panel section 42.
  • the central control means automatically directs the plasma into container 22 keeping track of the volume as it does so.
  • the central control means automatically diverts, by valve 16c, the emerging plasma fluid stream to container 23. In that instance, upon the emergence of the buffy coat and the keying of the BUFFY COAT data entry switch 44, the central control means diverts the emerging buffy coat into container 22 again keeping track of its volume since the volume pumped into the centrifuge equals the volume energizing therefrom.
  • the collection of the buffy coat will continue preferably in accordance with both the predetermined buffy coat volume as well as the number of cycles, also a predetermined condition by the physician. If this most preferred embodiment is employed, then a representative example might be as follows. Assume, that the predetermined volume and cycle conditions are set as follows: 350 mls of plasma, 250 mls of buffy coat, and 5 cycles. In each cycle, the apparatus will collect 250/5 or 50 mls of buffy coat before ending the cycle and thereupon emptying the centrifuge bowl and returning predominantly erythrocytes and perhaps excess plasma to the patient. Prior to the collection of the 50 mls, plasma will emerge from the centrifuge and will be collected in container 22 either until the full 350 mls are collected or, until the buffy coat emerges.
  • the central control means will direct the further collection of plasma, if needed, in order to reach the 350 ml predetermined volume and then collect an additional 50 mls of buffy coat.
  • the total volume to be contained within container 22, will then equal 600 mls and would be indicated on display 46 as it is accumulated.
  • the central control means of the apparatus automatically keeps track of the volumes as they are collected thereby facilitating the institution of a convenient number of cycles whereby the removal of large blood volumes from the patient is avoided. Not only is patient safety enhanced thereby, but the automated nature of the procedure further increases safety since, in accordance with the programmed data supplied to the central control means, the operator need not attempt to keep track of plasma and leukocyte enriched volumes, while still being assured that the final solution for treatment will contain the predetermined and desired leukocyte concentration.
  • the most preferred embodiment of the photoactivatable patient treatment system includes container 20 for providing an anti-coagulation agent to the patient's blood as it is obtained from the patient.
  • container 20 for providing an anti-coagulation agent to the patient's blood as it is obtained from the patient.
  • This may be advantageously accomplished by connecting container 20 to the tubing connected to the patient and controlling the flow from container 20 by means of an infusion pump 11.
  • an infusion pump 11 it has been found preferable to employ a peristaltic or roller type pump which is suitable for high precision, low volume delivery.
  • Stepper motors have, however, the undesirable characteristic of sometimes failing to advance after receiving a signal to do so in a mode of action that can be best described as "stuttering". Like cardiac fibrillation, such stuttering fails to deliver fluid volume and is accordingly undesirable.
  • the instant invention overcomes the limitations of known chopper devices inasmuch as the instant invention not only provides a signal responsive to stepper motor shaft rotation speed but, also provides signals which indicate when such rotation is really stuttering, i.e. a sequential forward and backward rotation without net forward rotation.
  • FIG. 4 and 5 show the stepper motor monitor of the instant invention.
  • Attached to the stepper motor output shaft 115 Is a periodic blocking means 110 shown as a disk having protruding tabs 111 at the periphery thereof.
  • sensors 113 for sensing the presence or absence of tabs 111 and generating a signal conveyed by wires 114 to the central control system.
  • sensors 113 show an illumination source and a detection source whereby the passage of light therebetween is blocked by the presence of tab 111, other obvious alternatives may be readily had such as the placement of source and detector on the same side, and the presence of tab 111 serving to reflect the light to the detector thereby generating an inverse signal (e.g. positive signal for presence versus positive signal for absence of tab 111) as compared to the shown arrangement.
  • the instant invention is capable of discriminating the stuttering due to the employment of multiple sensors in combination with the unique spacing characteristics of tabs 111 versus spaces 112.
  • Examination of Figure 5 will clearly show that the preferred embodiment utilizes a space 112 having an area approximately twice that of the area per tab 111.
  • the spacing of sensors 113 and their size are carefully regulated so that one sensor constantly remains unblocked, i.e. over a space 112, while the other sensor may also be in a space 112 or as shown, over a tab 111.
  • Signals from leads 114 are accepted alternately by the central processing control system so that information regarding continued rotation is ensured. Thus, if one sensor provides an "on" signal, the next signal that must be received is an "off" signal from the other sensor.
  • Stuttering of the stepper motor would result in a repetition of the first "on * signal prior to receiving a "off” signal and thus, such a failure would be immediately detectable.
  • the continuous receipt of on/off signals from altering sensors would indicate the desired continuous rotation of the stepper motor and thus the delivery of solution through the infusion pump connected thereto.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP85307808A 1984-10-29 1985-10-29 Kontrollvorrichtung für eine Pumpe für die Photoaktivierung in einem Patientenbehandlungssystem Withdrawn EP0180453A3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/665,826 US4623328A (en) 1984-10-29 1984-10-29 Pump monitor for photoactivation patient treatment system
US665826 1984-10-29

Publications (2)

Publication Number Publication Date
EP0180453A2 true EP0180453A2 (de) 1986-05-07
EP0180453A3 EP0180453A3 (de) 1987-10-07

Family

ID=24671714

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85307808A Withdrawn EP0180453A3 (de) 1984-10-29 1985-10-29 Kontrollvorrichtung für eine Pumpe für die Photoaktivierung in einem Patientenbehandlungssystem

Country Status (4)

Country Link
US (1) US4623328A (de)
EP (1) EP0180453A3 (de)
JP (1) JPS61109578A (de)
CA (1) CA1249756A (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2223575A (en) * 1988-09-02 1990-04-11 Alcatel Business Systems Optical position encoder
GB2241324A (en) * 1989-11-10 1991-08-28 Asahi Optical Co Ltd Photo-interrupter
US5244461A (en) * 1989-03-10 1993-09-14 Graseby Medical Limited Infusion pump with occlusion sensitive shutoff
FR2768572A1 (fr) * 1997-09-16 1999-03-19 Eaton Sa Monaco Actionneur pas-a-pas a detection de blocage

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681568A (en) 1984-10-29 1987-07-21 Mcneilab, Inc. Valve apparatus for photoactivation patient treatment system
US4728788A (en) * 1984-12-28 1988-03-01 Gilbarco, Inc. Position encoder apparatus
JPH0642716Y2 (ja) * 1986-07-18 1994-11-09 株式会社タイトー テレビゲーム機の操作装置
US5304113A (en) * 1986-11-21 1994-04-19 The Mcw Research Foundation, Inc. Method of eradicating infectious biological contaminants
US4775625A (en) * 1986-11-21 1988-10-04 The Medical College Of Wisconsin, Inc. Inactivating enveloped viruses with a merocyanine dye
US5039483A (en) * 1987-03-10 1991-08-13 The Medical College Of Wisconsin, Inc. Antiprotozoan method
US4915683A (en) * 1986-11-21 1990-04-10 The Medical College Of Wisconsin, Inc. Antiviral method, agents and apparatus
US4965446A (en) * 1989-04-20 1990-10-23 Ivac Corporation Optical interrupter system with vibration compensation
DE3921756C1 (de) * 1989-07-01 1991-01-03 Teldix Gmbh, 6900 Heidelberg, De
US5174961A (en) * 1991-01-18 1992-12-29 Hemotec, Inc. High sensitivity coagulation detection apparatus
FR2679648B1 (fr) * 1991-07-24 1996-04-12 Schlumberger Ind Sa Transmetteur analogique de position et de sens de rotation.
US5378227A (en) * 1992-08-11 1995-01-03 Cobe Laboratories, Inc. Biological/pharmaceutical method and apparatus for collecting and mixing fluids
JPH07181536A (ja) * 1993-12-22 1995-07-21 Nikon Corp 手振れ補正カメラ
US5711654A (en) * 1995-06-07 1998-01-27 Baxter International Inc. Peristaltic pump with rotor position sensing employing a reflective object sensor
IL126366A (en) * 1996-03-29 2011-10-31 Therakos Inc Use of a photoactivatable compound in the manufacture of a medicament for the treatment of an infection
EP0892599A4 (de) 1996-04-09 2001-05-16 Therakos Inc Verfahren zum entfernen von psoralen aus biologischen flüssigkeiten
US5951509A (en) * 1996-11-22 1999-09-14 Therakos, Inc. Blood product irradiation device incorporating agitation
JP4166432B2 (ja) * 1997-07-10 2008-10-15 セラコス・インコーポレイテッド 腸又は膀胱の炎症性疾病の処置
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US6277337B1 (en) 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US7025877B1 (en) 1999-06-03 2006-04-11 Baxter International Inc. Processing set for processing and treating a biological fluid
US6565802B1 (en) 1999-06-03 2003-05-20 Baxter International Inc. Apparatus, systems and methods for processing and treating a biological fluid with light
US7445756B2 (en) 1999-06-03 2008-11-04 Fenwal, Inc. Fluid processing sets and organizers for the same
US6219584B1 (en) 1999-07-09 2001-04-17 Therakos, Inc. Method and system for determining an effective amount of light energy to delivery to fluids having targets for the light energy
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US8722422B2 (en) 1999-09-03 2014-05-13 Therakos, Inc. Uninterrupted flow pump apparatus and method
US6723062B1 (en) 1999-09-03 2004-04-20 Baxter International Inc. Fluid pressure actuated blood pumping systems and methods with continuous inflow and pulsatile outflow conditions
US20060178612A9 (en) * 1999-09-03 2006-08-10 Baxter International Inc. Blood processing systems with fluid flow cassette with a pressure actuated pump chamber and in-line air trap
US6495366B1 (en) 1999-09-03 2002-12-17 Therakos, Inc. Uninterrupted flow pump apparatus and method
US6949079B1 (en) * 1999-09-03 2005-09-27 Baxter International Inc. Programmable, fluid pressure actuated blood processing systems and methods
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US6793643B1 (en) 2000-04-21 2004-09-21 Therakos, Inc. Low extracorporeal volume treatment system
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
TW590780B (en) 2000-06-02 2004-06-11 Gambro Inc Additive solutions containing riboflavin
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
DE10224750A1 (de) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Vorrichtung zur Behandlung einer medizinischen Flüssigkeit
US7935074B2 (en) 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
US20080058712A1 (en) * 2006-08-31 2008-03-06 Plahey Kulwinder S Peritoneal dialysis machine with dual voltage heater circuit and method of operation
US8272857B2 (en) * 2008-02-22 2012-09-25 Medtronic Xomed, Inc. Method and system for loading of tubing into a pumping device
US8192401B2 (en) 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
WO2011008858A1 (en) 2009-07-15 2011-01-20 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US8720913B2 (en) 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
DE102010053973A1 (de) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medizinisches Gerät mit einer Heizung
EP2654825B1 (de) 2010-12-20 2017-08-02 Fresenius Medical Care Holdings, Inc. Medizinische flüssigkeitskassetten sowie entsprechende systeme und verfahren
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
WO2012154352A1 (en) 2011-04-21 2012-11-15 Fresenius Medical Care Holdings, Inc. Medical fluid pumping systems and related devices and methods
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
EP3461510B1 (de) * 2017-10-02 2022-04-27 Fenwal, Inc. Systeme und verfahren zur rückführung behandelter mononuklearer zellen in eine blooo-quelle

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814934A (en) * 1972-11-10 1974-06-04 Gilbert & Barker Mfg Co Pulse generating apparatus responsive to shaft rotation
SE366591B (de) * 1973-02-06 1974-04-29 L Swiden
US4398906A (en) * 1979-12-11 1983-08-16 Frederic A. Bourke, Jr. Method for externally treating the blood
US4367435A (en) * 1980-12-15 1983-01-04 Ivac Corporation Motor control system
US4447191A (en) * 1981-12-15 1984-05-08 Baxter Travenol Laboratories, Inc. Control circuit for a blood fractionation apparatus
US4498843A (en) * 1982-08-02 1985-02-12 Schneider Philip H Insulin infusion pump
US4498983A (en) * 1983-05-26 1985-02-12 Baxter Travenol Laboratories, Inc. Pressure cuff draw mode enhancement system and method for a single needle blood fractionation system

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2223575A (en) * 1988-09-02 1990-04-11 Alcatel Business Systems Optical position encoder
GB2223575B (en) * 1988-09-02 1992-11-04 Alcatel Business Systems Drive mechanism with optical encoder
US5244461A (en) * 1989-03-10 1993-09-14 Graseby Medical Limited Infusion pump with occlusion sensitive shutoff
GB2241324A (en) * 1989-11-10 1991-08-28 Asahi Optical Co Ltd Photo-interrupter
FR2768572A1 (fr) * 1997-09-16 1999-03-19 Eaton Sa Monaco Actionneur pas-a-pas a detection de blocage
EP0908999A1 (de) * 1997-09-16 1999-04-14 Eaton S.A.M. Schrittmotor mit Blockiererkennung

Also Published As

Publication number Publication date
JPS61109578A (ja) 1986-05-28
EP0180453A3 (de) 1987-10-07
CA1249756A (en) 1989-02-07
JPH0531424B2 (de) 1993-05-12
US4623328A (en) 1986-11-18

Similar Documents

Publication Publication Date Title
US4623328A (en) Pump monitor for photoactivation patient treatment system
EP0181732B1 (de) Gerät zur Bestrahlung von Blutteilen
US4578056A (en) Patient photopheresis treatment apparatus and method
US4573961A (en) Electronic control methods for puvapheresis apparatus
US4573962A (en) Cassette drawer assembly for photoactivation patient treatment system
US4573960A (en) Three phase irradiation treatment process
US4737140A (en) Irradiation chamber for photoactivation patient treatment system
EP0240149B1 (de) Beleuchtungsanordnung für ein System zur Behandlung eines Patienten durch Photoaktivierung
EP0240154B1 (de) Pumpenkörper zum Anschluss einer Bestrahlungskammer an ein System zur Behandlung eines Patienten durch Photoaktivierung
US4596547A (en) Valve apparatus for photoactivation patient treatment system
EP0240153B1 (de) Einwegtemperaturfühler für ein System zur Behandlung eines Patienten durch Photoaktivierung
EP0241123B1 (de) Ventileinrichtung für ein System zur Behandlung eines Patienten durch Photoaktivierung
US4643710A (en) Valve apparatus for photoactivation patient treatment system
EP0239255A1 (de) Zerlegbare peristaltische Pumpe, für ein System zur Behandlung eines Patienten durch Photoaktivierung
US4687464A (en) Zero insertion force socket for photoactivation patient treatment system
EP0240152B1 (de) Bestrahlungskammer für ein System zur Behandlung eines Patienten durch Photoaktivierung
EP0239256A1 (de) On-line-system zur gleichzeitigen Bestrahlungsbehandlung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): DE FR GB IT

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): DE FR GB IT

17P Request for examination filed

Effective date: 19880311

17Q First examination report despatched

Effective date: 19890927

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19901204

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HARTRANFT, THOMAS PAUL